| Year |
Citation |
Score |
| 2018 |
Ehrenkranz R, Lam C, Petkov VI, Dilts D, Cheng S, Solis A, Negoita S. Quality Assessment of Tumor Size Data Collection for Pancreatic and Breast Cancer in SEER. Journal of Registry Management. 45: 161-166. PMID 31490911 |
0.56 |
|
| 2017 |
Parker C, Snyder R, Jefford M, Dilts D, Wolfe R, Millar J. A Randomized Controlled Trial of an Additional Funding Intervention to Improve Clinical Trial Enrollment. Journal of the National Comprehensive Cancer Network : Jnccn. 15: 1104-1110. PMID 28874595 DOI: 10.6004/Jnccn.2017.0150 |
0.452 |
|
| 2017 |
Massett HA, Dilts DM, Bailey R, Berktold J, Ledsky R, Atkinson NL, Mishkin G, Denicoff A, Padberg RM, Allen MP, Silver K, Carrington K, Johnson LE. Raising Public Awareness of Clinical Trials: Development of Messages for a National Health Communication Campaign. Journal of Health Communication. 1-13. PMID 28339327 DOI: 10.1080/10810730.2017.1290715 |
0.489 |
|
| 2016 |
Massett HA, Dilts DM, Miskin G, Bailey R, Ledsky R, Atkinson N, Denicoff A, Padberg RM, Allen M, Silver K, Carrington K, Malik SM, Johnson L. Will a national communication campaign to increase awareness of clinical trials work? Journal of Clinical Oncology. 34: 6537-6537. DOI: 10.1200/Jco.2016.34.15_Suppl.6537 |
0.442 |
|
| 2015 |
Perry D, Sperling R, Katz R, Berry D, Dilts D, Hanna D, Salloway S, Trojanowski JQ, Bountra C, Krams M, Luthman J, Potkin S, Gribkoff V, Temple R, Wang Y, et al. Building a roadmap for developing combination therapies for Alzheimer's disease. Expert Review of Neurotherapeutics. 15: 327-33. PMID 25708309 DOI: 10.1586/14737175.2015.996551 |
0.324 |
|
| 2015 |
Stephenson D, Perry D, Bens C, Bain LJ, Berry D, Krams M, Sperling R, Dilts D, Luthman J, Hanna D, McKew J, Temple R, Fields FO, Salloway S, Katz R. Charting a path toward combination therapy for Alzheimer's disease. Expert Review of Neurotherapeutics. 15: 107-13. PMID 25540951 DOI: 10.1586/14737175.2015.995168 |
0.311 |
|
| 2015 |
Parker C, Millar JL, Dilts DM, Jefford M, Wolfe R, Snyder RD. A randomized controlled trial (RCT) to improve enrollment to cancer clinical trials. Journal of Clinical Oncology. 33: 6514-6514. DOI: 10.1200/Jco.2015.33.15_Suppl.6514 |
0.493 |
|
| 2014 |
Dilts DM. Time has come to raise the bar in oncology clinical trials. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 32: 1186-7. PMID 24638007 DOI: 10.1200/Jco.2013.54.5277 |
0.529 |
|
| 2014 |
Dilts DM, Cheng SK, Stover Fiscalini A, Thompson CK, Hogarth M, Esserman L. Barriers to creating the next-generation cancer registry. Journal of Clinical Oncology. 32: e17682-e17682. DOI: 10.1200/Jco.2014.32.15_Suppl.E17682 |
0.613 |
|
| 2013 |
Denicoff AM, McCaskill-Stevens W, Grubbs SS, Bruinooge SS, Comis RL, Devine P, Dilts DM, Duff ME, Ford JG, Joffe S, Schapira L, Weinfurt KP, Michaels M, Raghavan D, Richmond ES, et al. The National Cancer Institute-American Society of Clinical Oncology Cancer Trial Accrual Symposium: summary and recommendations. Journal of Oncology Practice / American Society of Clinical Oncology. 9: 267-76. PMID 24130252 DOI: 10.1200/Jop.2013.001119 |
0.53 |
|
| 2013 |
Grazier KL, Trochim WM, Dilts DM, Kirk R. Estimating return on investment in translational research: methods and protocols. Evaluation & the Health Professions. 36: 478-91. PMID 23925706 DOI: 10.1177/0163278713499587 |
0.32 |
|
| 2013 |
Dilts DM. A "three-plus-one" evaluation model for clinical research management. Evaluation & the Health Professions. 36: 464-77. PMID 23908383 DOI: 10.1177/0163278713499019 |
0.379 |
|
| 2013 |
Hirsch BR, Califf RM, Cheng SK, Tasneem A, Horton J, Chiswell K, Schulman KA, Dilts DM, Abernethy AP. Characteristics of oncology clinical trials: insights from a systematic analysis of ClinicalTrials.gov. Jama Internal Medicine. 173: 972-9. PMID 23699837 DOI: 10.1001/Jamainternmed.2013.627 |
0.705 |
|
| 2013 |
Lopez-Chavez A, Thomas A, Rajan A, Steinberg SM, Dilts DM, Doyle A, Giaccone G. CUSTOM (Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies trial): A radical redesign of clinical trial structure—Use of mass customization and product postponement. Journal of Clinical Oncology. 31: 6524-6524. DOI: 10.1200/Jco.2013.31.15_Suppl.6524 |
0.494 |
|
| 2013 |
Massett H, Jaeckle KA, Dilts DM, Denicoff A, Souhan E, Hopkins JR, Mann BS. Rapid online feedback to improve clinical trial accrual: CODEL anaplastic glioma (AG) (NCCTG/Alliance N0577) as a model. Journal of Clinical Oncology. 31: 1596-1596. DOI: 10.1200/Jco.2013.31.15_Suppl.1596 |
0.459 |
|
| 2013 |
Cheng SK, Dilts DM. Building expertise in translational processes through partnerships with schools of business Translational Research in Biomedicine. 3: 74-81. DOI: 10.1159/000343022 |
0.507 |
|
| 2012 |
Yee D, Haddad T, Albain K, Barker A, Benz C, Boughey J, Buxton M, Chien AJ, DeMichele A, Dilts D, Elias A, Haluska P, Hogarth M, Hu A, Hytlon N, et al. Adaptive trials in the neoadjuvant setting: a model to safely tailor care while accelerating drug development. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 4584-6; author reply. PMID 23169510 DOI: 10.1200/Jco.2012.44.1022 |
0.335 |
|
| 2012 |
Dilts DM. Robbing peter to pay paul: financing clinical trial follow-up. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 1404-5. PMID 22454422 DOI: 10.1200/Jco.2011.41.3120 |
0.511 |
|
| 2012 |
Dilts DM, Rosenblum D, Trochim WM. A virtual national laboratory for reengineering clinical translational science. Science Translational Medicine. 4: 118cm2. PMID 22277966 DOI: 10.1126/Scitranslmed.3002951 |
0.469 |
|
| 2012 |
Dilts DM, Cheng SK. The importance of doing trials right while doing the right trials. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 3-5. PMID 22072734 DOI: 10.1158/1078-0432.Ccr-11-2586 |
0.691 |
|
| 2012 |
Massett H, Jaeckle KA, Hopkins JR, Mann BS, Denicoff A, Dilts DM. Intervention to increase site activations for multicenter trials to improve accrual. Journal of Clinical Oncology. 30: e16569-e16569. DOI: 10.1200/Jco.2012.30.15_Suppl.E16569 |
0.352 |
|
| 2012 |
Hirsch BR, Mitchell A, Cheng SK, Tasneem A, Schulman KA, Dilts DM, Abernethy AP. Improving the impact of clinical research: A systematic analysis of kidney cancer trials. Journal of Clinical Oncology. 30: 6051-6051. DOI: 10.1200/Jco.2012.30.15_Suppl.6051 |
0.711 |
|
| 2012 |
Cheng SK, Hirsch BR, Califf RM, Tasneem A, Schulman KA, Abernethy AP, Dilts DM. Geographic and network analysis of oncology trials: Portfolio assessment of ClinicalTrials.gov. Journal of Clinical Oncology. 30: 6047-6047. DOI: 10.1200/Jco.2012.30.15_Suppl.6047 |
0.649 |
|
| 2011 |
Dilts DM, Cheng SK, Wiltrout RH, Dahut WL, Bronez M, Helman LJ. Strategic alignment of clinical trials at the National Cancer Institute Center for Cancer Research: Development of the clinical mission and baseline portfolio metrics. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: e16619. PMID 28022808 DOI: 10.1200/jco.2011.29.15_suppl.e16619 |
0.675 |
|
| 2011 |
Stahl DC, Cheng SK, Lee E, Dilts DM. Benchmarking of oncology clinical trial metrics across AACI member centers. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: e16613. PMID 28022780 DOI: 10.1200/jco.2011.29.15_suppl.e16613 |
0.69 |
|
| 2011 |
Lethert KH, Cheng SK, Nauman DJ, Dilts DM, Sandler A, Chui SY. Implementation of a prospective screening tool for breast cancer clinical trial eligibility at an NCI designated cancer center. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 6052. PMID 28021874 DOI: 10.1200/Jco.2011.29.15_Suppl.6052 |
0.639 |
|
| 2011 |
Massett HA, Parreco LK, Padberg RM, Richmond ES, Rienzo ME, Leonard CE, Quesenbery W, Killiam HW, Johnson LE, Dilts DM. AccrualNet: Addressing Low Accrual Via a Knowledge-Based, Community of Practice Platform. Journal of Oncology Practice / American Society of Clinical Oncology. 7: e32-9. PMID 22379429 DOI: 10.1200/Jop.2011.000272 |
0.354 |
|
| 2011 |
Kitterman DR, Cheng SK, Dilts DM, Orwoll ES. The prevalence and economic impact of low-enrolling clinical studies at an academic medical center. Academic Medicine : Journal of the Association of American Medical Colleges. 86: 1360-6. PMID 21952064 DOI: 10.1097/Acm.0B013E3182306440 |
0.6 |
|
| 2011 |
Cheng SK, Dietrich MS, Dilts DM. Predicting accrual achievement: monitoring accrual milestones of NCI-CTEP-sponsored clinical trials. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 1947-55. PMID 21447723 DOI: 10.1158/1078-0432.Ccr-10-1730 |
0.694 |
|
| 2011 |
Massett H, Parreco LK, Padberg RM, Richmond E, Dilts DM. AccrualNet: A novel approach to addressing clinical trial accruals through a knowledge-based, community of practice platform. Journal of Clinical Oncology. 29: e16621-e16621. DOI: 10.1200/Jco.2011.29.15_Suppl.E16621 |
0.424 |
|
| 2011 |
Cheng SK, Dilts DM. Clinical trial development as a predictor of accrual performance - Response Clinical Cancer Research. 17: 4615. DOI: 10.1158/1078-0432.Ccr-11-0673 |
0.706 |
|
| 2010 |
Cheng SK, Dietrich MS, Dilts DM. A sense of urgency: Evaluating the link between clinical trial development time and the accrual performance of cancer therapy evaluation program (NCI-CTEP) sponsored studies. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 5557-63. PMID 21062929 DOI: 10.1158/1078-0432.Ccr-10-0133 |
0.716 |
|
| 2010 |
Dilts DM, Cheng SK, Crites JS, Sandler AB, Doroshow JH. Phase III clinical trial development: a process of chutes and ladders. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 5381-9. PMID 21062928 DOI: 10.1158/1078-0432.Ccr-10-1273 |
0.709 |
|
| 2010 |
Dilts DM. Early warning: an ailing canary in the mine. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 3799-800. PMID 20644096 DOI: 10.1200/Jco.2010.29.8810 |
0.516 |
|
| 2010 |
Dilts D. US cancer trials may go the way of the Oldsmobile. Nature Medicine. 16: 632. PMID 20526311 DOI: 10.1038/Nm0610-632 |
0.485 |
|
| 2010 |
Salomon RM, Blackford JU, Rosenbloom ST, Seidel S, Clayton EW, Dilts DM, Finder SG. Openness of patients' reporting with use of electronic records: psychiatric clinicians' views. Journal of the American Medical Informatics Association : Jamia. 17: 54-60. PMID 20064802 DOI: 10.1197/Jamia.M3341 |
0.302 |
|
| 2010 |
Dilts DM, Adjei AA, Mandrekar SJ, Buckner JC, Minasian LM, Rienzo M, Ledsky R, Massett H. Impact of trial development time on accruals at CCOPs: The case of the MARVEL trial. Journal of Clinical Oncology. 28: e16505-e16505. DOI: 10.1200/Jco.2010.28.15_Suppl.E16505 |
0.455 |
|
| 2010 |
Cheng SK, Dietrich MS, Finnigan S, Dilts DM. Early indicators of accrual success: Time-to-first-patient and accrual performance at an anticipated enrollment milestone-A study of NCI-CTEP-sponsored clinical trials. Journal of Clinical Oncology. 28: 6001-6001. DOI: 10.1200/Jco.2010.28.15_Suppl.6001 |
0.716 |
|
| 2009 |
Cheng S, Dietrich M, Finnigan S, Sandler A, Crites J, Ferranti L, Wu A, Dilts D. A sense of urgency: Evaluating the link between clinical trial development time and the accrual performance of CTEP-sponsored studies. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: CRA6509. PMID 27937600 DOI: 10.1200/jco.2009.27.18_suppl.cra6509 |
0.422 |
|
| 2009 |
Dilts DM, Sandler AB, Cheng SK, Crites JS, Ferranti LB, Wu AY, Finnigan S, Friedman S, Mooney M, Abrams J. Steps and time to process clinical trials at the Cancer Therapy Evaluation Program. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 1761-6. PMID 19255315 DOI: 10.1200/Jco.2008.19.9133 |
0.696 |
|
| 2009 |
Dilts D, Ridner SH, Franco A, Murphy B. Patients with cancer and e-mail: implications for clinical communication. Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer. 17: 1049-56. PMID 19050941 DOI: 10.1007/S00520-008-0538-6 |
0.327 |
|
| 2009 |
Cheng S, Dietrich M, Finnigan S, Sandler A, Crites J, Ferranti L, Wu A, Dilts D. A sense of urgency: Evaluating the link between clinical trial development time and the accrual performance of CTEP-sponsored studies Journal of Clinical Oncology. 27: CRA6509-CRA6509. DOI: 10.1200/Jco.2009.27.18_Suppl.Cra6509 |
0.716 |
|
| 2009 |
Pathak SD, Dilts DM, Mahadevan S. Investigating population and topological evolution in a complex adaptive supply network Journal of Supply Chain Management. 45: 54-67. DOI: 10.1111/J.1745-493X.2009.03171.X |
0.655 |
|
| 2008 |
Dilts DM, Sandler AB, Cheng S, Crites J, Ferranti L, Wu A, Bookman MA, Thomas JP, Ostroff J. Accrual to clinical trials at selected comprehensive cancer centers. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 6543. PMID 27949834 DOI: 10.1200/Jco.2008.26.15_Suppl.6543 |
0.71 |
|
| 2008 |
Dilts DM, Sandler A, Cheng S, Crites J, Ferranti L, Wu A, Gray R, MacDonald J, Marinucci D, Comis R. Development of clinical trials in a cooperative group setting: the eastern cooperative oncology group. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 3427-33. PMID 18519773 DOI: 10.1158/1078-0432.Ccr-07-5060 |
0.669 |
|
| 2007 |
Pathak SD, Dilts DM, Biswas G. On the evolutionary dynamics of supply network topologies Ieee Transactions On Engineering Management. 54: 662-672. DOI: 10.1109/Tem.2007.906856 |
0.656 |
|
| 2006 |
Dilts DM, Sandler AB, Baker M, Cheng SK, George SL, Karas KS, McGuire S, Menon GS, Reusch J, Sawyer D, Scoggins M, Wu A, Zhou K, Schilsky RL. Processes to activate phase III clinical trials in a Cooperative Oncology Group: the Case of Cancer and Leukemia Group B. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 24: 4553-7. PMID 17008694 DOI: 10.1200/Jco.2006.06.7819 |
0.688 |
|
| 2006 |
Dilts DM, Sandler AB. Invisible barriers to clinical trials: the impact of structural, infrastructural, and procedural barriers to opening oncology clinical trials. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 24: 4545-52. PMID 17008693 DOI: 10.1200/Jco.2005.05.0104 |
0.525 |
|
| 2006 |
Dilts DM, Sandler AB, Baker M, Cheng S, McGuire S, Menon G, Wu A, Karas K, Sawyer D, Schilsky RL. A timing and process flow analysis of opening clinical trials within an oncology cooperative group setting: The case of the CALGB Journal of Clinical Oncology. 24: 6015-6015. DOI: 10.1200/Jco.2006.24.18_Suppl.6015 |
0.655 |
|
| 2005 |
Dilts DM. Practice variation: the Achilles' heel in quality cancer care. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 5881-2. PMID 16087953 DOI: 10.1200/Jco.2005.05.034 |
0.357 |
|
| 2004 |
Dilts DM, Sandler A, Moore S, Browning D, Johnson A, Pardeshi A, Rouch D, Xie B. Structural, infrastructural and procedural barriers to oncology clinical trials Journal of Clinical Oncology. 22: 6010-6010. DOI: 10.1200/jco.2004.22.90140.6010 |
0.337 |
|
| 1999 |
Dilts DM, Khamalah J. A comparison of ordinal analysis techniques in medical resource usage research Electronic Notes in Discrete Mathematics. 2: 51-68. DOI: 10.1016/S1571-0653(04)00014-9 |
0.341 |
|
| Show low-probability matches. |